GFR-话题@MedSci

#GFR#

483篇内容 | 2469人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534580, encodeId=b87c153458053, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：瑞普替尼在携带KIT/PDGFRA突变的晚期胃肠道间质瘤患者中的显著疗效, objectType=article, longId=219181, objectId=102e219181e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=102e219181e4, replyNumber=0, likeNumber=79, createdTime=2021-10-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=102e219181e4, moduleTitle=Clin Cancer Res：瑞普替尼在携带KIT/PDGFRA突变的晚期胃肠道间质瘤患者中的显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=102e219181e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534579, encodeId=7b9015345e90c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, objectType=article, longId=219107, objectId=6aae21910e96, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aae21910e96, replyNumber=0, likeNumber=59, createdTime=2021-10-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aae21910e96, moduleTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aae21910e96)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534578, encodeId=002a15345e867, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), objectType=article, longId=218470, objectId=7b082184e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b082184e0a7, replyNumber=0, likeNumber=68, createdTime=2021-10-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b082184e0a7, moduleTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b082184e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534577, encodeId=6f7c15345e7a9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Science Translational Medicine: 上海交大医学院朱亮团队等揭示克服肺癌EGFR靶向治疗耐药新机制, objectType=article, longId=218325, objectId=21f0218325fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21f0218325fd, replyNumber=0, likeNumber=64, createdTime=2021-10-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21f0218325fd, moduleTitle=Science Translational Medicine: 上海交大医学院朱亮团队等揭示克服肺癌EGFR靶向治疗耐药新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21f0218325fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534576, encodeId=f0b715345e646, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=29, createdTime=2021-10-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534575, encodeId=9c9715345e52f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索, objectType=article, longId=218122, objectId=df5c21812297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df5c21812297, replyNumber=0, likeNumber=87, createdTime=2021-10-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df5c21812297, moduleTitle=Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df5c21812297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534574, encodeId=1b9a15345e455, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, objectType=article, longId=217868, objectId=7f5c21e868c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f5c21e868c1, replyNumber=0, likeNumber=76, createdTime=2021-09-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f5c21e868c1, moduleTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f5c21e868c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534573, encodeId=3b6115345e34c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AJKD：儿童和青少年透析开始时估计GFR和死亡率的关系, objectType=article, longId=217609, objectId=e01e21e60950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01e21e60950, replyNumber=0, likeNumber=86, createdTime=2021-09-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01e21e60950, moduleTitle=AJKD：儿童和青少年透析开始时估计GFR和死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01e21e60950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534572, encodeId=60ef15345e2b0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）, objectType=article, longId=217564, objectId=4a9821e5642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9821e5642b, replyNumber=0, likeNumber=67, createdTime=2021-09-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9821e5642b, moduleTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9821e5642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534571, encodeId=837c15345e1fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, objectType=article, longId=217452, objectId=1a0421e45297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0421e45297, replyNumber=0, likeNumber=91, createdTime=2021-09-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0421e45297, moduleTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0421e45297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534570, encodeId=3f7e15345e014, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, objectType=article, longId=217428, objectId=aa6621e428d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6621e428d6, replyNumber=0, likeNumber=77, createdTime=2021-09-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6621e428d6, moduleTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6621e428d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534569, encodeId=498f15345699d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CJASN：蛋白尿、肾小球滤过率(GFR)快速下降与髋关节和骨盆骨折风险的相关性, objectType=article, longId=217233, objectId=0def21e23391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0def21e23391, replyNumber=0, likeNumber=83, createdTime=2021-09-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0def21e23391, moduleTitle=CJASN：蛋白尿、肾小球滤过率(GFR)快速下降与髋关节和骨盆骨折风险的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0def21e23391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534567, encodeId=e78f153456ebc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=79, createdTime=2021-09-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534566, encodeId=589015345662e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=30, createdTime=2021-09-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534568, encodeId=e8741534568c5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展, objectType=article, longId=217030, objectId=d87e21e03024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87e21e03024, replyNumber=0, likeNumber=24, createdTime=2021-09-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87e21e03024, moduleTitle=【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87e21e03024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534565, encodeId=05a915345650a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=直播：EGFR靶向药该如何排兵布阵？, objectType=article, longId=215950, objectId=5a9621595035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a9621595035, replyNumber=0, likeNumber=82, createdTime=2021-08-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a9621595035, moduleTitle=直播：EGFR靶向药该如何排兵布阵？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a9621595035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534564, encodeId=11df1534564e8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, objectType=article, longId=215743, objectId=7f20215e43ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f20215e43ec, replyNumber=0, likeNumber=32, createdTime=2021-08-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f20215e43ec, moduleTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f20215e43ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534563, encodeId=512d15345633a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=75, createdTime=2021-08-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534562, encodeId=63b5153456274, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, objectType=article, longId=215464, objectId=286f215464c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286f215464c0, replyNumber=0, likeNumber=32, createdTime=2021-08-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286f215464c0, moduleTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286f215464c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534561, encodeId=3b7b153456148, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, objectType=article, longId=215314, objectId=b54d215314e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b54d215314e4, replyNumber=0, likeNumber=82, createdTime=2021-08-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b54d215314e4, moduleTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b54d215314e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：瑞普替尼在携带KIT/PDGFRA突变的晚期胃肠道间质瘤患者中的显著疗效

2021-10-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用

2021-10-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG)

2021-10-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Science Translational Medicine: 上海交大医学院朱亮团队等揭示克服肺癌EGFR靶向治疗耐药新机制

2021-10-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2021-10-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索

2021-10-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据

2021-09-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AJKD：儿童和青少年透析开始时估计GFR和死亡率的关系

2021-09-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）

2021-09-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

2021-09-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物

2021-09-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CJASN：蛋白尿、肾小球滤过率(GFR)快速下降与髋关节和骨盆骨折风险的相关性

2021-09-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期

2021-09-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2021-09-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展

2021-09-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

直播：EGFR靶向药该如何排兵布阵？

2021-08-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）

2021-08-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2021-08-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

2021-08-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况

2021-08-06

科室
- - 订阅+
  - 更多科室
工具
服务